Study wrapper · #917
Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRβ/Ang1/Tie2/VEGF signaling pathway.
Shi Y, Dong X, Zhu C, et al. Scientific reports. 2026.
DOI: 10.1038/s41598-026-62312-wPubMed: 42471364
Editor's note
This is a single mechanistic study in a mouse controlled-cortical-impact model, so the evidence is preliminary and animal-only. It reports that semaglutide is associated with upregulated PDGF-BB signaling and improved vascular and barrier markers after injury. Human relevance remains undetermined, and the results should be read as hypothesis-generating rather than clinically actionable.
Plain-language abstract
In a mouse model of traumatic brain injury, semaglutide was associated with increased blood-vessel formation and better blood-brain barrier integrity through several signaling pathways. The findings are preclinical and have not been shown in humans.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026